GLP-1 for PCOS Polycystic ovary syndrome (PCOS) affects roughly one in ten women in the UK and is closely linked to insulin resistance, even in women who aren't overweight
Overexpression of TLR7 exacerbates the autoimmune response by stimulating extra-follicular B cell responses and the formation of spontaneous germinal centers (Spt-GCs) (56)
Lower doses reduce GI side effects
Large proteins and peptides, like insulin, tend to have low levels in breast milk because of their size and structure
The test analyzes variants in GLP1R (GLP-1 receptor sensitivity), GIPR (glucose-dependent insulinotropic peptide response), FTO (appetite regulation and metabolic rate), and MC4R (satiety signaling) genes
In reality, up to 70% of patients stop GLP-1 treatment within a year most often due to: High cost (GLP-1s can cost $1,000+ per month without insurance) Loss of insurance coverage for weight loss treatment Side effects such as nausea, diarrhea, constipation, or fatigue A Misconceptions some patients stop once they lose initial weight, believing they no longer need the medication 2